MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$2,226,177
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from purchases of commo...
Loss on impairment of goodwill
Accounts payable
Others
Negative Cash Flow Breakdown
Net loss
Principal payments of notes paya...
Inventories
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Loss on impairment of entadfi
-
-
0
0
Loss on impairment of intangibles
-
-
0
-
Amortization of debt discount - related party
-
-
0
0
Interest accrued on note payable
-
-
-
0
Purchase of property and equipment
-
-
0
0
Interest accrued on note payable related party
-
-
-
0
Net cash provided by (used in) investing activities
0
0
0
0
Change in fair value of warrant liabilities
-
-
-
-1,934,000
Change in fair value of series d warrant liability
-
-
10,377,638
-
Loss on impairment of inventory of entadfi
-
-
-
0
Amortization of debt discounts
0
0
3,922
115,196
Change in fair value of series d derivative liability
-
-
3,593,333
216,000
Deferred tax benefit
-
-
0
0
Change in fair value of subscription agreement liability - related party
0
0
-
-
Change in fair value of subscription agreement liability
-
-
0
0
Amortization of deferred offering costs
-
-
0
-
Net periodic pension benefit
0
0
-619,399
-
Gain on settlement of contingent warrant liabilities
-
-
-944,694
0
Gain on forgiveness of accounts payable
0
0
944,694
-
Loss on extinguishment of note payable
-
-
0
5,384,719
Disposal of property and equipment
0
0
-250
-551
Loss on extinguishment of series c preferred stock
-
-
0
196,244
Net loss
-2,867,303
-4,214,875
5,669,687
-8,783,702
Loss on issuance of preferred stock and warrants
-
-
1,131,000
2,543,329
Loss on impairment of goodwill
486,000
8,134,000
12,000
-12,000
Depreciation and amortization
2,632
5,398
3,336
3,387
Net periodic pension benefit
-
-
-
246,080
Stock-based compensation
7,359
22,305
4,234
9,795
Change in fair value of contingent warrant liabilities
-400
1,612
26,559
-36
Change in fair value of series e warrant liability
-
-
-4,486,847
-
Change in fair value of series d derivative liability
136,471
-3,955,778
-
-
Change in fair value of series e derivative liability
0
-2,072,590
1,539,014
-
Accounts receivable
-41,450
-270,735
293,929
-9,559
Inventories
76,247
-11,654
-462
1,417
Investor receivable
0
-50,000
50,000
-
Prepaid expenses and other current assets
-67,603
83,396
499,228
-169,489
Deferred offering costs
-
-
75,000
150,000
Prepaid expenses, long-term
-
-
0
0
Accounts payable
312,116
-224,779
-45,687
-775,167
Loss on impairment of inventory of entadfi
-
-
0
-
Accrued expenses
-28,548
-62,543
-142,150
-427,930
Proceeds from issuance of notes payable - related party
-
-
0
0
Net cash used in operating activities
-1,918,067
-2,121,481
-3,090,585
-3,177,829
Payment of financing costs
-
-
0
0
Payment for redemption of series c preferred stock
0
0
0
0
Proceeds from exercise of preferred investment options, net
-
-
0
0
Proceeds from issuance of note payable
0
247,196
460,875
400,000
Proceeds from exercise of stock options
-
-
0
0
Principal payments of notes payable
96,802
0
164,188
5,410,029
Proceeds from issuance of series d preferred stock and warrants
-
-
0
9,301,200
Proceeds from exercise of warrants
0
384,842
0
0
Proceeds from issuance of series e preferred stock and warrants
-
-
6,250,000
-
Cash in lieu of shares
98
250
0
0
Proceeds from issuance of series c preferred stock and warrants
-
-
0
-
Proceeds from purchases of common stock in connection with the eloc
4,265,275
0
21
-21
Net cash provided by financing activities
4,168,375
631,788
6,546,708
4,291,150
Effect of exchange rate changes on cash
-24,131
-14,889
927,975
-560,280
Net increase (decrease) in cash
2,226,177
-1,504,582
4,384,098
553,041
Cash, beginning of period
3,716,072
5,220,654
836,556
646,500
Cash, end of period
5,942,249
3,716,072
5,220,654
836,556
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from purchases
of common stock in...
$4,265,275
(-33.27%↓ Y/Y)
Net cash provided by
financing activities
$4,168,375
(15.31%↑ Y/Y)
Canceled cashflow
$96,900
Net increase
(decrease) in cash
$2,226,177
(713.30%↑ Y/Y)
Canceled cashflow
$1,942,198
Principal payments of
notes payable
$96,802
(-93.70%↓ Y/Y)
Cash in lieu of shares
$98
(-89.42%↓ Y/Y)
Loss on impairment of
goodwill
$486,000
(-95.78%↓ Y/Y)
Accounts payable
$312,116
(214.41%↑ Y/Y)
Change in fair value of
series d derivative...
$136,471
Prepaid expenses and
other current assets
-$67,603
(66.43%↑ Y/Y)
Accounts receivable
-$41,450
(-164.27%↓ Y/Y)
Stock-based compensation
$7,359
(-87.78%↓ Y/Y)
Depreciation and
amortization
$2,632
(-68.84%↓ Y/Y)
Change in fair value of
contingent warrant...
-$400
(96.01%↑ Y/Y)
Net cash used in
operating activities
-$1,918,067
(43.75%↑ Y/Y)
Effect of exchange rate
changes on cash
-$24,131
(95.75%↑ Y/Y)
Canceled cashflow
$1,054,031
Net loss
-$2,867,303
(73.74%↑ Y/Y)
Inventories
$76,247
(4.79%↑ Y/Y)
Accrued expenses
-$28,548
(-186.86%↓ Y/Y)
Buy us a coffee
Onconetix, Inc. (ONCO)
Onconetix, Inc. (ONCO)